



PATENT

Case Docket No. UCLA019.001A

Date: August 31, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Tontono et al.
Appl. No. : 10/755,720
Filed : January 12, 2004
For : RECIPROCAL REGULATION
OF INFLAMMATION AND
LIPID METABOLISM BY
LIVER X RECEPTORS
Examiner : Unknown
Group Art Unit : 1614

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 31, 2004

(Date)

Marina L. Gordey, Reg. No. 52,950

TRANSMITTAL LETTER


Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with forty-one (41) references.
- (X) An Establishment of Right of Assignee to Take Action and Revocation and Power of Attorney with a copy of an Assignment.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Tontonoz et al.
App. No. : 10/755,720
Filed : January 12, 2004
For : RECIPROCAL REGULATION OF
INFLAMMATION AND LIPID
METABOLISM BY LIVER X
RECEPTORS
Examiner : Unknown
Group Art Unit : 1614

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 41 references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 31, 2004

By: _____

Marina L. Gondey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580



FORM PTO-143

SEP 02 2004

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

ATTY. DOCKET NO.
UCLA019.001AAPPLICATION NO.
10/755,720APPLICANT
Tontonoz et al.FILING DATE
January 12, 2004GROUP
1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---------------------|-----------------|------|------|-------|----------|---------------------------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---------------------|-----------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

| | | |
|--|----|--|
| | 1 | Callejas, N.A. et al. (2000) "Regulation of cyclooxygenase 2 expression in Hepatocytes by CCAAT/enhancer-binding proteins," <i>Gastroenterology</i> 119:493-501. |
| | 2 | Castrillo, A. et al. (2000) "Inhibition of I κ B kinase and I κ B phosphorylation by 15-deoxy- $\Delta^{12,14}$ -prostaglandin J ₂ in activated murine macrophages," <i>Mol. and Cell Biol.</i> 20:1692-1698. |
| | 3 | Castrillo, A. et al. (2001) "Inhibition of the nuclear factor κ B (NF- κ B) pathway by tetracyclic kaurene diterpenes in macrophages," <i>J. Bio. Chem.</i> 276:15854-15860. |
| | 4 | Chawla, A. et al. (2001) "A PPAR γ -LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis," <i>Mol. Cell</i> 7:161-171. |
| | 5 | Chawla, A. et al. (2001) "PPAR- γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation," <i>Nat. Med.</i> 7:48-52. |
| | 6 | Chen, L.M. et al. (1996) " <i>Salmonella</i> ssp. are cytotoxic for cultured macrophages," <i>Mol. Microb.</i> 21:1101-1115. |
| | 7 | Detmers, P.A. et al. (2000) "Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice," <i>J. Immunol.</i> 165:3430-3435. |
| | 8 | Febbraio, M. et al. (2000) "Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice," <i>J. Clin. Invest.</i> 105: 1049-1056. |
| | 9 | Fu, X. et al. (2001) "27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells," <i>J. Biol. Chem.</i> 276:38378-38387. |
| | 10 | Galis, Z.S. et al. (1995) "Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases," <i>PNAS USA</i> 92:402-406. |
| | 11 | Galis, Z.S. et al. (2002) "Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling," <i>Circ. Res.</i> 91:852-859. |
| | 12 | Glass, C.K. et al. (2001) "Atherosclerosis: the road ahead," <i>Cell</i> 104:503-516. |

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | |
|--|----------------------------------|-------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO. UCLA019.001A | APPLICATION NO. 10/755,720 |
| | APPLICANT Tontonoz et al. | |
| | FILING DATE January 12, 2004 | GROUP 1614 |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---------------------|---|
| 13 | Gu, L. et al. (1998) "Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice," <i>Mol. Cell</i> 2:275-281. |
| 14 | Hansson, G.K. (1999) "Inflammation and immune response in atherosclerosis," <i>Curr. Atheroscler. Rep.</i> 1:150-155. |
| 15 | Herrlich, P. (2001) "Cross-talk between glucocorticoid receptor and AP-1," <i>Oncogene</i> 20:2465-2475. |
| 16 | Jiang, C. et al. (1998) "PPAR- γ agonists inhibit production of monocyte inflammatory cytokines," <i>Nature</i> 391:82-86. |
| 17 | Joseph, S.B. et al. (2002) "Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors," <i>J. Biol. Chem.</i> 277:11019-11025. |
| 18 | Joseph, S.B. et al. (2002) "Synthetic LXR ligand inhibits the development of atherosclerosis in mice," <i>PNAS USA</i> 99:7604-7609. |
| 19 | Joseph, S.B. et al. (2003) "Reciprocal regulation of inflammation and lipid metabolism by liver X receptors," <i>Nature Med.</i> 9:213-219. |
| 20 | Karin, M. et al. (2001) "AP-1-glucocorticoid receptor crosstalk taken to a higher level," <i>J. Endocrinol.</i> 169:447-451. |
| 21 | Kuhlencordt, P.J. (2001) "Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice," <i>Circulation</i> 103:3099-3104. |
| 22 | Lafitte, B.A. et al. (2001) "Autoregulation of the human liver X receptor α promoter," <i>Mol. Cell. Biol.</i> 21:7558-7568. |
| 23 | Lafitte, B.A. et al. (2002) "Orphan Nuclear Receptors find a home in the arterial wall," <i>Curr. Atheroscl. Rep.</i> 4:213-221. |
| 24 | Li M. et al. (2000) "Peroxisome proliferator-activated receptor γ -dependent repression of the inducible nitric oxide synthase gene," <i>Mol. & Cell. Bio.</i> 20:4699-4707. |
| 25 | Liu, S-X. et al. (1998) "Oxidized cholesterol in oxidized low density lipoprotein may be responsible for the inhibition of LPS-induced nitric oxide production in macrophages," <i>Atherosclerosis</i> 136:43-49. |
| 26 | Lowenstein, C.J. (1993) "Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon γ and lipopolysaccharide," <i>PNAS USA</i> 90:9730-9734. |
| 27 | Lusis, A.J. (2000) "Atherosclerosis," <i>Nature</i> 407:233-241. |
| 28 | Mestre, J.R. et al. (2001) "Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/monocytic cells," <i>J. Biol. Chem.</i> 276:3977-3982. |
| 29 | Moore, K.J. et al. (2001) "The role of PPAR- γ in macrophage differentiation and cholesterol uptake," <i>Nat. Med.</i> 7:41-47. |
| 30 | Nagy, L. et al. (1998) "Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR γ ," <i>Cell</i> 93:229-240. |
| 31 | Nissen, R.M. et al. (2000) "The glucocorticoid receptor inhibits NF κ B by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain," <i>Gen. & Dev.</i> 14:2314-2329. |
| 32 | Pasterkamp, G. et al. (2000) "Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery," <i>Atherosclerosis</i> 150:245-253. |
| 33 | Repa, J.J. et al. (2000) "The role of orphan nuclear receptors in the regulation of cholesterol homeostasis," <i>Annu. Rev. Cell Dev. Bio.</i> 16:459-481. |
| 34 | Repa, J.J. et al. (2002) "The liver X receptor gene team: potential new players in atherosclerosis," <i>Nat. Med.</i> 8:1243-1248. |
| 35 | Ricote, M. et al. (1998) "The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation," <i>Nature</i> 391:79-81. |

| | |
|--|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |

| | | |
|--|----------------------------------|-------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO. UCLA019.001A | APPLICATION NO. 10/755,720 |
| | APPLICANT Tontonoz et al. | |
| | FILING DATE January 12, 2004 | GROUP 1614 |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
|---------------------|--|--|
| | 36 | Sheu, M.Y. et al. (2002) "Topical peroxisome proliferator activated receptor- α activators reduce inflammation in irritant and allergic contact dermatitis models," <i>J. Invest. Dermatol.</i> 118 :94-101. |
| | 37 | Straus, D.S. et al. (2000) "15-Deoxy- $\Delta^{12,14}$ -prostaglandin J ₂ inhibits multiple steps in the NF-kB signaling pathway." <i>PNAS USA</i> 97 :4844-4849. |
| | 38 | Suzuki, H. et al. (1997) "A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection." <i>Nature</i> 386 :292-295. |
| | 39 | Tangirala, R.K. et al. (2002) "Identification of macrophage liver X receptors as inhibitors in atherosclerosis." <i>PNAS USA</i> 99 :11896-11901. |
| | 40 | Tontonoz, P. et al. (1998) "PPAR γ promotes Monocyte/Macrophage differentiation and uptake of oxidized LDL." <i>Cell</i> 93 :241-252. |
| | 41 | Wu, Z.L. et al. (1997) Oxidized low-density lipoprotein decreases the induced nitric oxide synthesis in rat mesangial cells." <i>Cell Bio. & Function</i> 16 :153-158. |

O:\DOCS\MXG\MXG-5821.DOC:vr
082504

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |